Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

NCT04252742 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Erenumab
DRUG: Placebo

Sponsor

Amgen